BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 17684033)

  • 1. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
    Kim SS
    Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
    Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
    Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
    Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
    Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.
    Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ
    Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
    Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
    Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.
    Perales MA; Ishill N; Lomazow WA; Weinstock DM; Papadopoulos EB; Dastigir H; Chiu M; Boulad F; Castro-Malaspina HR; Heller G; Jakubowski AA; O'Reilly RJ; Small TN; Young JW; Kernan NA
    Bone Marrow Transplant; 2007 Sep; 40(5):481-6. PubMed ID: 17618322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
    Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.
    Park JH; Lee HJ; Kim SR; Song GW; Lee SK; Park SY; Kim KC; Hwang SH; Park JS
    Korean J Intern Med; 2014 Sep; 29(5):630-6. PubMed ID: 25228839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin for refractory acute graft-versus-host disease.
    Ghez D; Rubio MT; Maillard N; Suarez F; Chandesris MO; Delarue R; Deau-Fischer B; Varet B; Hermine O; Buzyn A
    Transplantation; 2009 Nov; 88(9):1081-7. PubMed ID: 19898203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
    Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
    Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel strategies for steroid-refractory acute graft-versus-host disease.
    Bolaños-Meade J; Vogelsang GB
    Curr Opin Hematol; 2005 Jan; 12(1):40-4. PubMed ID: 15604890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report.
    Piton G; Larosa F; Minello A; Becker MC; Mantion G; Aubin F; Deconinck E; Hillon P; Di Martino V
    Liver Transpl; 2009 Jul; 15(7):682-5. PubMed ID: 19562700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and novel therapies in acute GVHD.
    Ho VT; Cutler C
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):223-37. PubMed ID: 18503988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation.
    Jaiswal SR; Zaman S; Chakrabarti A; Sehrawat A; Bansal S; Gupta M; Chakrabarti S
    Transpl Immunol; 2016 Nov; 39():46-51. PubMed ID: 27577170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.
    Sellar RS; Peggs KS
    Future Oncol; 2012 Dec; 8(12):1549-65. PubMed ID: 23231517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience.
    Miano M; Cuzzubbo D; Terranova P; Giardino S; Lanino E; Morreale G; Castagnola E; Dini G; Faraci M
    Bone Marrow Transplant; 2009 Mar; 43(5):423-7. PubMed ID: 18850021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.
    Schroeder T; Haas R; Kobbe G
    Expert Rev Hematol; 2010 Oct; 3(5):633-51. PubMed ID: 21083479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.